Capstone Therapeutics (CAPS) to Release Quarterly Earnings on Tuesday

Capstone Therapeutics (NASDAQ:CAPS) will likely be issuing its Q4 2025 results before the market opens on Tuesday, April 7th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $12.5130 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, April 7, 2026 at 4:00 PM ET.

Capstone Therapeutics Price Performance

Shares of Capstone Therapeutics stock opened at $0.58 on Friday. The stock has a market capitalization of $5.25 million, a price-to-earnings ratio of -0.61 and a beta of -1.27. Capstone Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.29. The company’s 50 day moving average price is $0.63 and its 200-day moving average price is $0.84. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.35 and a current ratio of 0.95.

Hedge Funds Weigh In On Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC purchased a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics as of its most recent SEC filing. 2.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capstone Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Capstone Therapeutics currently has an average rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.